We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.7B
AUM Growth
+$120M
Cap. Flow
-$25.9M
Cap. Flow %
-0.96%
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$17.5M
2
NVRO
NEVRO CORP.
NVRO
+$15.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$14.2M
4
NVS icon
Novartis
NVS
+$11.9M
5
BIIB icon
Biogen
BIIB
+$11.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.3M
2
MOH icon
Molina Healthcare
MOH
+$18.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.9M
4
PFE icon
Pfizer
PFE
+$11.2M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.69%
2 Real Estate 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$18.7B
$25.9M 0.96%
562,467
+116,393
+26% +$5.65M
TMO icon
27
Thermo Fisher Scientific
TMO
$214B
$24.3M 0.9%
139,120
-88,900
-39% -$14.9M
COR icon
28
Cencora
COR
$60.7B
$24.1M 0.89%
254,887
-75,800
-23% -$6.75M
IBB icon
29
iShares Biotechnology ETF
IBB
$9.52B
$23.6M 0.87%
227,910
-6,000
-3% -$591K
MCK icon
30
McKesson
MCK
$101B
$23.5M 0.87%
142,800
+29,700
+26% +$4.5M
IDXX icon
31
Idexx Laboratories
IDXX
$44.1B
$21.4M 0.79%
132,352
– –
AZN icon
32
AstraZeneca
AZN
$266B
$18.8M 0.7%
275,300
+43,400
+19% +$2.83M
PBYI icon
33
Puma Biotechnology
PBYI
$402M
$17.7M 0.66%
202,537
-57,663
-22% -$3.23M
XBI icon
34
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$17.5M 0.65%
226,460
– –
SRPT icon
35
Sarepta Therapeutics
SRPT
$1.64B
$17.2M 0.64%
511,600
– –
GSK icon
36
GSK
GSK
$104B
$15.5M 0.57%
287,200
– –
CNC icon
37
Centene
CNC
$30.1B
$15.4M 0.57%
385,200
+96,600
+33% +$3.65M
OHI icon
38
Omega Healthcare
OHI
$15B
$15.1M 0.56%
458,616
– –
NVRO
39
DELISTED
NEVRO CORP.
NVRO
$14.5M 0.54%
+194,621
New +$15.6M
PVLA
40
Palvella Therapeutics
PVLA
$2.15B
$14.4M 0.53%
35,470
-13,781
-28% -$4.03M
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
$14.1M 0.52%
+150,800
New +$9.23M
CI icon
42
Cigna
CI
$76.1B
$14M 0.52%
83,900
– –
EXEL icon
43
Exelixis
EXEL
$14.1B
$13.6M 0.5%
551,647
– –
SBRA icon
44
Sabra Healthcare REIT
SBRA
$5.38B
$13.3M 0.49%
550,990
– –
WELL.PRI
45
DELISTED
Welltower Inc.
WELL.PRI
$13.3M 0.49%
200,000
– –
DHC
46
Diversified Healthcare Trust
DHC
$2.17B
$13.2M 0.49%
646,554
– –
ZBH icon
47
Zimmer Biomet
ZBH
$18.4B
$13.1M 0.49%
105,369
– –
MPT
48
Medical Properties Trust
MPT
$2.81B
$13M 0.48%
1,007,717
– –
CRL icon
49
Charles River Laboratories
CRL
$11.3B
$12.9M 0.48%
127,100
– –
PRTK
50
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$12.8M 0.48%
533,000
-229,581
-30% -$5.08M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Tekla Capital Management held 152 positions worth $2.7B, up 4.7% from $2.58B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q2 2017 filing shows 13 new, 22 increased, 27 reduced and 8 closed positions. Its largest new stake was NEVRO CORP.: 194,621 shares worth $14.5M. The largest sale was Vertex Pharmaceuticals, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2017 buy was NEVRO CORP.: 194,621 shares worth $14.5M.
  • Tekla Capital Management added most to Merck in Q2 2017, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $28.3M.
  • Tekla Capital Management fully exited Molina Healthcare in Q2 2017, selling an estimated $18.4M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.7B portfolio in Q2 2017.
  • Tekla Capital Management opened 13 new positions and closed 8 in Q2 2017.
  • Tekla Capital Management's portfolio value rose 4.7% quarter-over-quarter to $2.7B.

Based on Tekla Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.